ArticleFrontiers in pharmacology2025
Evaluating the role of astragalus polysaccharide in modulating immune infiltration and enhancing prognostic biomarkers in pediatric acute myeloid leukemia.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The multidimensional signaling of ELANE: from congenital hematopoietic failure to immune microenvironment crosstalk and targeted interventions.Cell communication and signaling : CCS · 2026Review
- Exploring Endoplasmic Reticulum Stress-Related Genes in Cartilage Defects: Implications for Diagnosis and Therapy.Combinatorial chemistry & high throughput screening · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Childhood acute myeloid leukemia (AML) constitutes a significant proportion of pediatric malignancies, with current treatment options remaining limited. This study aimed to investigate the role of Astragalus polysaccharide (APS) in immune infiltration and prognosis of pediatric AML. Methods: Differentially expressed genes (DEGs) were identified from the GEO database (dataset GSE2191), and APS-related genes (APSRGs) were obtained from the Swiss Target Prediction platform. DEGs with |logFC| > 1 and p < 0.05 were intersected with APSRGs to identify APS-related differentially expressed genes (APSRDEGs), visualized using a Venn diagram. A protein-protein interaction (PPI) network analysis was conducted to identify hub genes. Gene Ontology (GO) and KEGG enrichment analyses were performed to determine biological processes (BP), cellular components (CC), molecular functions (MF), and relevant pathways associated with the hub genes. Correlation analysis, receiver operating characteristic (ROC) curve analysis, and immune infiltration analysis were conducted to assess the relationship between hub genes and pediatric AML. Results: The GSE2191 dataset was divided into pediatric AML (PAML) and control groups. A total of 1,881 DEGs were identified, of which 20 were APSRDEGs. PPI network analysis revealed that 13 APSRDEGs were interconnected, and nine hub genes were identified: Conclusion: This study identified nine hub genes related to APS in pediatric AML. These findings suggest that APS may significantly affect immune infiltration and prognosis in pediatric AML, highlighting its potential as a therapeutic modulator for the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.